ARS Pharmaceuticals, Inc.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 20, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (see signature page)
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Richard Lowenthal and Kathleen Scott, and each of them, his or her true and lawful attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact or their substitute or substitutes may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | Title | Date |
|---|---|---|
| /s/ Richard Lowenthal | President, Chief Executive Officer, and Director | March 20, 2025 |
| Richard Lowenthal, M.S., MSEL | (Principal Executive Officer) | |
| /s/ Kathleen D. Scott | Chief Financial Officer | March 20, 2025 |
| Kathleen D. Scott | (Principal Financial and Accounting Officer) | |
| /s/ Pratik Shah | Chairman of the Board of Directors | March 20, 2025 |
| Pratik Shah, Ph.D. | ||
| /s/ Peter Kolchinsky | Director | March 20, 2025 |
| Peter Kolchinsky, Ph.D. | ||
| /s/ Rajeev Dadoo | Director | March 20, 2025 |
| Rajeev Dadoo, Ph.D. | ||
| /s/ Brenton L. Saunders | Director | March 20, 2025 |
| Brenton L. Saunders | ||
| /s/ Phillip Schneider | Director | March 20, 2025 |
| Phillip Schneider | ||
| /s/ Michael Kelly | Director | March 20, 2025 |
| Michael Kelly | ||
| /s/ Laura Shawver | Director | March 20, 2025 |
| Laura Shawver, Ph.D. | ||
| /s/ Peter A. Thompson | Director | March 20, 2025 |
| Peter A. Thompson, M.D. | ||
| /s/ Saqib Islam | Director | March 20, 2025 |
| Saqib Islam, J.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.